SCM
CTMX icon

Sterling Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Sterling Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.38K Buy
+1,969
New +$7.52K ﹤0.01% 2393
2018
Q3 		– Sell
-37,751
Closed -$863K – 868
2018
Q2 		$863K Sell
37,751
-45
-0.1% -$1.15K 0.01% 664
2018
Q1 		$1.07M Hold
37,796
– – 0.01% 587
2017
Q4 		$798K Buy
+37,796
New +$784K 0.01% 697

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Sterling Capital Management's CTMX Position: Q2 2026 in Review

Sterling Capital Management opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 1,969 shares worth $7.38K. The stake represents ﹤0.01% of the portfolio and ranks #2393 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in CTMX as recently as Q2 2018.

Sterling Capital Management first reported a position in CTMX in Q4 2017 and has held it in 4 quarters since. The position peaked at $1.07M in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Sterling Capital Management held 1,969 shares of CytomX Therapeutics worth $7.38K as of Q2 2026.
  • CytomX Therapeutics was a new Sterling Capital Management position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2393 holding.
  • Sterling Capital Management first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 4 quarters since.
  • Sterling Capital Management's CytomX Therapeutics position peaked at $1.07M in Q1 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.